It's ETF Battles time, and in today's episode we'll be comparing the two biotech giants iShares Biotechnology ETF (IBB) Vs. SPDR S&P ETF (XBI).

On a day where broad markets are correcting strongly we are on record forecasting a bullish second half of 2018 for biotechnology stocks.

Although the stock market displayed weakness last week as I suggested it would, bulls aren’t going down easily.

Except for one gas utility fund (GASFX), only Health Care mutual funds outperformed the S&P 500 over multiple long and short periods (including 2008) with “reasonable” volatility for return generated.

Top scoring weekly returns: Buy and Hold 1 Year

Health care ETFs offer market beating performance, but these areas represent the strongest industry ETFs so far this year.